Exagen Reports Record Q1 Revenue, Beats Estimates, Reaffirms 2026 Guidance
XGN sits 29% above its 52-week low of $2.59.
Summary
Exagen Inc. reported strong first-quarter 2026 financial results, exceeding revenue estimates and improving adjusted EBITDA, while reaffirming its full-year guidance.
Key Events · Earnings and Guidance · XGN
-
Record Q1 Revenue Exceeds Estimates
Exagen reported record total revenue of $17.3 million for Q1 2026, a 12% increase year-over-year, surpassing the IBES consensus estimate of $16.4 million.
-
Adjusted EBITDA Loss Narrows
The adjusted EBITDA loss improved by 14% to $2.2 million in Q1 2026, compared to $2.5 million in Q1 2025, indicating better operational efficiency.
-
Full-Year 2026 Guidance Reaffirmed
The company maintained its full-year 2026 revenue guidance, expecting to achieve between $70 million and $73 million.
-
Strong Cash Position
Exagen ended the quarter with approximately $21.5 million in cash and cash equivalents, ahead of expectations and consistent with its strategy.
Analysis · XGN · Industrial Applications And Services
Exagen Inc. delivered a strong first quarter, surpassing analyst revenue estimates and showing operational improvements. The company achieved record revenue and narrowed its adjusted EBITDA loss, indicating progress towards profitability. Reaffirming full-year guidance provides stability and confidence in its outlook, especially for a company of this size. The increased cash position also suggests effective financial management.
At the time of this filing, XGN was trading at $3.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $71M. The 52-week trading range was $2.59 to $12.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.